346 related articles for article (PubMed ID: 33327450)
1. Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment: Significance for Chemo- and Immunotherapies.
Klemba A; Bodnar L; Was H; Brodaczewska KK; Wcislo G; Szczylik CA; Kieda C
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33327450
[TBL] [Abstract][Full Text] [Related]
2. Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer.
Pereira M; Matuszewska K; Jamieson C; Petrik J
Front Endocrinol (Lausanne); 2021; 12():772349. PubMed ID: 34867818
[TBL] [Abstract][Full Text] [Related]
3. Influence of hypoxia inducible factors on the immune microenvironment in ovarian cancer.
Duechler M; Peczek L; Szubert M; Suzin J
Anticancer Res; 2014 Jun; 34(6):2811-9. PubMed ID: 24922644
[TBL] [Abstract][Full Text] [Related]
4. Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer.
Greppi M; Tabellini G; Patrizi O; Candiani S; Decensi A; Parolini S; Sivori S; Pesce S; Paleari L; Marcenaro E
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791364
[TBL] [Abstract][Full Text] [Related]
5. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy.
Schaaf MB; Garg AD; Agostinis P
Cell Death Dis; 2018 Jan; 9(2):115. PubMed ID: 29371595
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia Reduction Sensitizes Refractory Cancers to Immunotherapy.
Jayaprakash P; Vignali PDA; Delgoffe GM; Curran MA
Annu Rev Med; 2022 Jan; 73():251-265. PubMed ID: 34699264
[TBL] [Abstract][Full Text] [Related]
7. Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors.
Eckert F; Zwirner K; Boeke S; Thorwarth D; Zips D; Huber SM
Front Immunol; 2019; 10():407. PubMed ID: 30930892
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-modulatory nanomaterials to relieve tumor hypoxic microenvironment and enhance immunotherapy: Where do we stand?
Yuan CS; Deng ZW; Qin D; Mu YZ; Chen XG; Liu Y
Acta Biomater; 2021 Apr; 125():1-28. PubMed ID: 33639310
[TBL] [Abstract][Full Text] [Related]
9. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer.
Chouaib S; Noman MZ; Kosmatopoulos K; Curran MA
Oncogene; 2017 Jan; 36(4):439-445. PubMed ID: 27345407
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer biology and immunotherapy.
Latha TS; Panati K; Gowd DS; Reddy MC; Lomada D
Int Rev Immunol; 2014 Oct; 33(5):428-40. PubMed ID: 24911597
[TBL] [Abstract][Full Text] [Related]
11. Vascular normalization: reshaping the tumor microenvironment and augmenting antitumor immunity for ovarian cancer.
Yu P; Wang Y; Yuan D; Sun Y; Qin S; Li T
Front Immunol; 2023; 14():1276694. PubMed ID: 37936692
[TBL] [Abstract][Full Text] [Related]
12. Genetic and epigenetic strategies for advancing ovarian cancer immunotherapy.
Cho Y; Milane L; Amiji MM
Expert Opin Biol Ther; 2019 Jun; 19(6):547-560. PubMed ID: 30933545
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of CD147 in ovarian cancer is initiated by the hypoxic microenvironment.
Yang H; Zou W; Chen B
Cell Biol Int; 2013 Oct; 37(10):1139-42. PubMed ID: 23686717
[TBL] [Abstract][Full Text] [Related]
14. Tumor Hypoxia: A Key Determinant of Microenvironment Hostility and a Major Checkpoint during the Antitumor Response.
Francis A; Venkatesh GH; Zaarour RF; Zeinelabdin NA; Nawafleh HH; Prasad P; Buart S; Terry S; Chouaib S
Crit Rev Immunol; 2018; 38(6):505-524. PubMed ID: 31002604
[TBL] [Abstract][Full Text] [Related]
15. Prospects and challenges for immunotherapy of ovarian cancer--what can we learn from the tumor microenvironment?
Chiriva-Internati M; Cobos E; Cannon MJ
Int Rev Immunol; 2011; 30(2-3):67-70. PubMed ID: 21557634
[TBL] [Abstract][Full Text] [Related]
16. Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer.
Nersesian S; Glazebrook H; Toulany J; Grantham SR; Boudreau JE
Front Immunol; 2019; 10():1782. PubMed ID: 31456796
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia.
Noman MZ; Hasmim M; Messai Y; Terry S; Kieda C; Janji B; Chouaib S
Am J Physiol Cell Physiol; 2015 Nov; 309(9):C569-79. PubMed ID: 26310815
[TBL] [Abstract][Full Text] [Related]
18. Exosomes derived from hypoxic epithelial ovarian cancer deliver microRNA-940 to induce macrophage M2 polarization.
Chen X; Ying X; Wang X; Wu X; Zhu Q; Wang X
Oncol Rep; 2017 Jul; 38(1):522-528. PubMed ID: 28586039
[TBL] [Abstract][Full Text] [Related]
19. Tumor Microenvironment and Nitric Oxide: Concepts and Mechanisms.
Vedenko A; Panara K; Goldstein G; Ramasamy R; Arora H
Adv Exp Med Biol; 2020; 1277():143-158. PubMed ID: 33119871
[TBL] [Abstract][Full Text] [Related]
20. Metabolic factors contribute to T-cell inhibition in the ovarian cancer ascites.
Gong Y; Yang J; Wang Y; Xue L; Wang J
Int J Cancer; 2020 Oct; 147(7):1768-1777. PubMed ID: 32208517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
